CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 760 enrolled
Drug / intervention
Clarithromycin (Klacid® MR)drug
Likely dose
Clarithromycin (Klacid® MR) 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01076153
NCT01076153N/ACompleted
CompareCT.gov

A Multi-center, Post-Marketing Observational Study to Identify the Recovery Time in Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR

Abbott·observational·Posted Feb 26, 2010·Updated Jul 12, 2011

In Brief

An observational study evaluating Clarithromycin (Klacid® MR) for Respiratory Tract Infection. Completed, enrolled 760 participants across 26 sites.

Detailed Summary

The investigators hypothesize that Klacid modified release (MR) shortens symptom recovery time in Thai patients with upper or lower respiratory tract infections.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Tract Infection
CountriesThailand
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 26, 2010
Enrollment StartDec 1, 2008
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.3 years ago

Interventions

Clarithromycin (Klacid® MR)drug

Klacid MR 500mg (clarithromycin)